KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trial.

Hideki Koizumi, Shigeru Honda, Tsutomu Yasukawa, Genichiro Kishino, Tetsuju Sekiryu, Andrea Schulze, Takuto Yamashita, Ursula Schmidt-Ott, Min Zhao, Xin Zhang, Alyson J Berliner, Karen W Chu, Kimberly Reed, Yenchieh Cheng, Rafia Bhore, Robert Vitti, Ikuko Fujita, Sergio Leal, Tomohiro Iida, PULSAR investigators

Jpn J Ophthalmol 70(1) 139-149

PMID41452565
PMCIDPMC12948824
DOI10.1007/s10384-025-01270-8
发表日期2025-12-26
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图;Fig. 4:森林图/亚组分析图。
摘要

摘要

PURPOSE: To evaluate the 1-year efficacy and safety of aflibercept 8 mg compared with aflibercept 2 mg in a pre-specified analysis of patients from Japan with neovascular age-related macular degeneration (nAMD) included in PULSAR. STUDY DESIGN: PULSAR (NCT04423718) was a global, phase 3, randomized, double-masked, non-inferiority study of adults with nAMD. Patients were randomized 1:1:1 to receive aflibercept 8 mg every 12 weeks (8q12), or every 16 weeks (8q16), or aflibercept 2 mg every 8 weeks (2q8), following three initial monthly doses in all groups. METHODS: This subgroup analysis of Japan and non-Japan cohorts from PULSAR evaluated changes from baseline in best-corrected visual acuity (BCVA), central subfield retinal thickness, durability and safety outcomes. RESULTS: In the Japan subgroup, least squares (LS) mean (95% CI) changes from baseline in BCVA at week 48 were +6.5 (+0.7, +12.3), +7.9 (+5.1, +10.6), and +4.7 (-0.5, +9.9) letters for patients in the 8q12 (n = 31), 8q16 (n = 33), and 2q8 (n = 33) groups, respectively. The majority of patients in the 8q12 (82.1%) and 8q16 (93.8%) groups maintained their randomized dosing intervals through Week 48. Ocular treatment-emergent adverse events were reported in 35.5%, 30.3%, and 39.4% of patients in the Japan subgroup in 8q12, 8q16, and 2q8 groups, respectively. Similar efficacy and safety results were observed in the non-Japan subgroup. CONCLUSION: Aflibercept 8 mg has similar efficacy and safety to aflibercept 2 mg when administered at extended dosing intervals in both the Japan and non-Japan subgroups, consistent with the overall PULSAR results.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Arithmetic mean change and LS mean (95% CI) change in BCVA by visit through 48 weeks of aflibercept treatment in the ( a) Japan and ( b) non-Japan subgroups. Full analysis set. Arithmetic mean changes based on OC prior to relevant ICE, LS mean changes based on MMRM. 2q8=aflibercept 2 mg every 8 weeks. 8q12=aflibercept 8 mg every 12 weeks. 8q16=aflibercept 8 mg every 16 weeks. BCVA best-corrected visual acuity. CI confidence interval. ETDRS Early Treatment Diabetic Retinopathy Study. ICE intercurrent event. LS least squares. MMRM mixed model repeated measures. OC observed cases.
非 KM Figure
Fig. 2Fig. 2 Proportion of patients without retinal fluid in the central subfield at week 16 and week 48 in the ( a) Japan and ( b) non-Japan subgroups. Full analysis set. Last observation carried forwards. One patient in the 8q12 cohort was missing/ungradable at weeks 16 and 48. 2q8=aflibercept 2 mg every 8 weeks. 8q12=aflibercept 8 mg every 12 weeks. 8q16=aflibercept 8 mg every 16 weeks.
非 KM Figure
Fig. 3Fig. 3 Arithmetic mean change and LS mean change (95% CI) in CRT by visit over 48 weeks of aflibercept treatment in the ( a ) Japan and ( b) non-Japan subgroups. Full analysis set. Arithmetic mean changes based on OC prior to relevant ICE, LS mean changes based on MMRM. 2q8=aflibercept 2 mg every 8 weeks. 8q12=aflibercept 8 mg every 12 weeks. 8q16=aflibercept 8 mg every 16 weeks. CI confidence interval. CRT central retinal thickness. ICE intercurrent event. LS least squares. MMRM mixed model repeated measures. OC observed cases
非 KM Figure
Fig. 4Fig. 4 Proportion of patients in the ( a) Japan and ( b) non-Japan subgroups receiving aflibercept 8 mg who maintained their randomized dosing intervals through week 48. *No patients in the 8q16 group from the Japan subgroup required their dosing intervals to be shortened to Q8. Data presented for patients who completed 48 weeks of treatment and completed the week 48 visit of the trial. 2q8=aflibercept 2 mg every 8 weeks. 8q12=aflibercept 8 mg every 12 weeks. 8q16=aflibercept 8 mg every 16 weeks. Q4, every 4 weeks. Q8, every 8 weeks. Q12, every 12 weeks. Q16, every 16 weeks.
非 KM Figure